Keywords: Sanofi-Aventis, Sanofi Pasteur, Alopexx, monoclonal antibodies, Infections, Dengue fever, Vaccines, Latin America

Sanofi-Aventis enters up to $375 million superbug antibody deal with Alopexx; Pasteur moves on Dengue fever

Article | 10 December 2009

Print This

French drug major Sanofi-Aventis and US biotechnology firm Alopexx Pharmaceuticals have entered a collaboration agreement and option for a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in